.jpg)
Large Pharmaceutical
Director, VP
Phase III
Oncology - Multiple Myeloma
Subscribe to our newsletter to receive the latest case studies.
A leading pharmaceutical company preparing for global launch faced an unexpected threat: new real world data presented at a major conference suggested a competitor’s drug might deliver superior clinical outcomes.
With payer negotiations approaching, leadership feared this comparative effectiveness finding could undermine their product’s value perception and delay HTA submission.
Internal teams needed a rapid response grounded in health economics and outcomes research (HEOR) and evidence generation to maintain confidence with payers, physicians, and field representatives.
Alkemi deployed the Access Threat Response System™ to deliver a coordinated plan to restore confidence and protect market access in 90 days.
Alkemi convened global and affiliate teams to review competitor abstracts, evaluate disease burden claims, and align on unified counter-messaging. This process identified critical gaps in the competitor’s evidence base while strengthening lessons learned from prior submissions.
We developed communication guides and objection-handling tools so the field force could demonstrate efficacy, safety, and value in payer discussions. Physicians and payers were equipped with clear insights to address questions in real time at upcoming conferences.
Our team investigated available electronic health records and claims data to generate new perspectives on treatment outcomes. These observational studies helped highlight inconsistencies in the competitor’s findings and supported alternative viewpoints that favored the client’s pharmaceutical product.
We designed a proactive plan for new abstracts, journal articles, and publications. This roadmap enabled continuous evidence generation, reinforced the product’s effectiveness and cost profile, and ensured future payer conversations were grounded in evolving research.
"When I presented the project output to our leadership, they said: ‘You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward.’"
Alkemi’s Access Threat Response System™ gave the client a clear, 90-day process to protect product value under immediate pressure.
Field teams were armed with evidence-backed arguments, payers received stronger evaluation of clinical trial and RWE data, and leadership regained confidence heading into negotiations.
The resulting publications and communication strategy positioned the therapy for stronger long-term adoption, reducing costly delays and enabling patient access.
When new data threatens product value, Alkemi helps clients pivot fast with the evidence, strategy, and insights needed to protect investments, strengthen submissions, and maintain market access.